He sets semaglutide's 14.9% average weight loss in its main obesity trial against tirzepatide's 20.9% at the top dose.
Recap by typeshit. Post by @drclaymoss on Instagram.
Early trial results suggest the shot could one day help people hold onto weight loss after they come off GLP-1 drugs.
Bodybuilder Sam Sulek gives his take on peptides in a short clip from Chris Williamson's show. His views are his own, not medical guidance.
Superpower frames apitegromab's FDA approval as a big step and ties it to concern that GLP-1 users can lose a lot of muscle along with fat.
The telehealth company is also adding blood testing services alongside the lower costs for its compounded GLP-1 options.
Meteo.gr reports strong weight loss results for amycretin, Novo Nordisk's next obesity candidate. Few details were given beyond the headline.
The Danish town that makes Ozempic and Wegovy is nicknamed Novo Town, a sign of how much these drugs have reshaped one place.
Loading…